RAASlääkkeiden

RAASlääkkeet, also known as Renin-Angiotensin-Aldosterone System inhibitors, are a class of medications that target the renin-angiotensin-aldosterone system (RAAS). This system plays a crucial role in regulating blood pressure and fluid balance in the body. Medications in this category work by interfering with the normal functioning of the RAAS, thereby lowering blood pressure and reducing strain on the cardiovascular system.

The RAASlääkkeet encompass several types of drugs, including ACE inhibitors (angiotensin-converting enzyme inhibitors), ARBs (angiotensin II receptor blockers), direct renin inhibitors, and aldosterone antagonists. Each of these drug classes targets a different step in the RAAS pathway. ACE inhibitors block the production of angiotensin II, a potent vasoconstrictor, while ARBs prevent angiotensin II from binding to its receptors. Direct renin inhibitors block the initial enzyme in the cascade, renin. Aldosterone antagonists block the effects of aldosterone, a hormone that promotes sodium and water retention.

These medications are widely prescribed for the management of various cardiovascular conditions. Their primary indications include hypertension (high blood pressure), heart failure, chronic kidney disease, and diabetic nephropathy. By reducing blood pressure and workload on the heart, RAASlääkkeet help prevent serious complications such as heart attack, stroke, and kidney failure. While generally well-tolerated, potential side effects can include cough (with ACE inhibitors), dizziness, and elevated potassium levels. It is essential for patients to use these medications under the guidance of a healthcare professional.